One Year Outcomes Among Children Identified With Celiac Disease Through A Mass Screening Program.

celiac disease outcomes screening

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
12 Apr 2024
Historique:
received: 16 11 2023
revised: 02 03 2024
accepted: 11 03 2024
medline: 15 4 2024
pubmed: 15 4 2024
entrez: 14 4 2024
Statut: aheadofprint

Résumé

Celiac disease (CD) mass screening remains controversial in part because of a paucity of data to support its benefit. The Autoimmunity Screening for Kids (ASK) study is a mass screening study for pediatric CD and type 1 diabetes in Colorado. This study prospectively follows children ages 1-17 years who screened positive for tissue transglutaminase IgA autoantibodies (tTGA) in the ASK study subsequently referred for diagnostic evaluation. Children diagnosed with CD by biopsy or serologic criteria were included in this study. Evaluation at baseline and 12 month follow up included demographics, laboratory studies, symptoms, health-related quality of life (HRQoL), anxiety/depression, and gluten-free diet (GFD) adherence. Paired student-t, chi-square, and Wilcoxon sign rank tests compared baseline and follow up data. For symptom scores, odds of improvement were assessed. Of the 52 children with CD enrolled, 42 children completed 12-month follow up. On the symptom questionnaire completed at diagnostic evaluation, 38/42 children reported one or more symptoms. CD mean symptom severity and frequency scores improved from baseline to follow up (p <0.001). Reported HRQoL scores improved among caregivers (p=0.002). There was no significant change in reported anxiety or depression. Iron deficiency without anemia was common at baseline (21/24 children, 87.5%) and normalized at follow up (11/21 children, 52.3%). 26/28 families reported good or excellent GFD adherence. This novel study of children with CD identified through a mass screening program demonstrated improvement in symptoms, quality of life, and iron deficiency after one year follow up. This demonstrates that there may be benefit to CD mass screening.

Sections du résumé

BACKGROUND BACKGROUND
Celiac disease (CD) mass screening remains controversial in part because of a paucity of data to support its benefit. The Autoimmunity Screening for Kids (ASK) study is a mass screening study for pediatric CD and type 1 diabetes in Colorado.
METHODS METHODS
This study prospectively follows children ages 1-17 years who screened positive for tissue transglutaminase IgA autoantibodies (tTGA) in the ASK study subsequently referred for diagnostic evaluation. Children diagnosed with CD by biopsy or serologic criteria were included in this study. Evaluation at baseline and 12 month follow up included demographics, laboratory studies, symptoms, health-related quality of life (HRQoL), anxiety/depression, and gluten-free diet (GFD) adherence. Paired student-t, chi-square, and Wilcoxon sign rank tests compared baseline and follow up data. For symptom scores, odds of improvement were assessed.
RESULTS RESULTS
Of the 52 children with CD enrolled, 42 children completed 12-month follow up. On the symptom questionnaire completed at diagnostic evaluation, 38/42 children reported one or more symptoms. CD mean symptom severity and frequency scores improved from baseline to follow up (p <0.001). Reported HRQoL scores improved among caregivers (p=0.002). There was no significant change in reported anxiety or depression. Iron deficiency without anemia was common at baseline (21/24 children, 87.5%) and normalized at follow up (11/21 children, 52.3%). 26/28 families reported good or excellent GFD adherence.
CONCLUSIONS CONCLUSIONS
This novel study of children with CD identified through a mass screening program demonstrated improvement in symptoms, quality of life, and iron deficiency after one year follow up. This demonstrates that there may be benefit to CD mass screening.

Identifiants

pubmed: 38615728
pii: S1542-3565(24)00352-5
doi: 10.1016/j.cgh.2024.03.030
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Marisa G Stahl (MG)

Digestive Health Institute, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States. Electronic address: marisa.stahl@childrenscolorado.org.

Zhaoxing Pan (Z)

Child Health Research Biostatistics Core, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Monique Germone (M)

Digestive Health Institute, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Sadie Nagle (S)

Digestive Health Institute, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Pooja Mehta (P)

Digestive Health Institute, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Mary Shull (M)

Digestive Health Institute, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Isabel Griffith (I)

Digestive Health Institute, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Brianne Shuler (B)

Digestive Health Institute, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Edward Hoffenberg (E)

Digestive Health Institute, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Iman Taki (I)

Barbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Cristy Geno-Rasmussen (C)

Barbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Marian J Rewers (MJ)

Barbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Jill M Norris (JM)

Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Edwin Liu (E)

Digestive Health Institute, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Classifications MeSH